Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

This study is currently recruiting participants.

Verified by Baker Heart Research Institute, September 2005

Sponsors and Collaborators:	Baker Heart Research Institute National Health and Medical Research Council, Australia Hoffmann-La Roche Diabetes Australia
Information provided by:	Baker Heart Research Institute
ClinicalTrials.gov Identifier:	NCT00168519

Purpose

The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscle during exercise.

Condition	Intervention
Diabetes Mellitus, Type 2	Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

MedlinePlus related topics: Diabetes Exercise and Physical Fitness

Drug Information available for: Dextrose Diltiazem Verapamil Dexverapamil Diltiazem hydrochloride Diltiazem malate Verapamil hydrochloride Nitric oxide Isosorbide Isosorbide dinitrate Isosorbide-5-mononitrate Sodium nitroprusside Nitroprusside

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study
Official Title:	Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

Further study details as provided by Baker Heart Research Institute:

Study Start Date:

October 2002

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients with type 2 diabetes

Non-smokers
Free of overt coronary disease (stress ECG)
Body mass index < 35 kg.m-2
Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
Unmedicated (diet controlled)

Healthy controls

Non-smokers
Free of overt coronary disease (ECG)
Body mass index < 30 kg.m-2
Fasting plasma glucose < 6.1 mmol.L-1
Unmedicated

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168519

Contacts

Contact: Bronwyn A Kingwell, A/Prof

03 9276 3261

b.kingwell@alfred.org.au

Locations

Australia, Victoria
Baker Heart Research Institute	Recruiting
Melbourne, Victoria, Australia, 8008
Contact: Bronwyn A Kingwell, A/Prof 9276 3261 b.kingwell@alfred.org.au

Sponsors and Collaborators

Baker Heart Research Institute

National Health and Medical Research Council, Australia

Hoffmann-La Roche

Diabetes Australia

Investigators

Principal Investigator:

Bronwyn A Kingwell, PhD

Baker Heart Research Institute

More Information

Study ID Numbers:	51/02
Study First Received:	September 14, 2005
Last Updated:	September 14, 2005
ClinicalTrials.gov Identifier:	NCT00168519
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Baker Heart Research Institute:

Diabetes Mellitus, Type 2
Blood Glucose
Exercise

Muscle Contraction
Nitric Oxide
Nitrates

Study placed in the following topic categories:

Isosorbide
Metabolic Diseases
Isosorbide-5-mononitrate
Diabetes Mellitus
Endocrine System Diseases
Isosorbide Dinitrate
Nitric Oxide

Verapamil
Diabetes Mellitus, Type 2
Diltiazem
Nitroprusside
Endocrinopathy
Glucose Metabolism Disorders
Metabolic disorder

Additional relevant MeSH terms:

Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Nitric Oxide Donors

ClinicalTrials.gov processed this record on January 13, 2009